The DOI matches its Crossref record; 294 of the 296 references it cites were found in a registry or an index.
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Open accessAbstract
The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may reflect the fact that the enrolled participants in clinical trials are already too advanced to derive a clinical benefit. Thus, well-validated biomarkers for the early detection and accurate diagnosis of the preclinical stages of AD will be crucial for therapeutic advancement. The combinatorial use of biomarkers derived from biological fluids, such as cerebrospinal fluid (CSF), with advanced molecular imaging and neuropsychological testing may eventually achieve the diagnostic sensitivity and specificity necessary to identify people in the earliest stages of the disease when drug modification is most likely possible. In this regard, positive amyloid or tau tracer retention on positron emission tomography imaging, low CSF concentrations of the amyloid-β 1-42 peptide, high CSF concentrations in total tau and phospho-tau, mesial temporal lobe atrophy on magnetic resonance imaging, and temporoparietal/precuneus hypometabolism or hypoperfusion on 18F-fluorodeoxyglucose positron emission tomography have all emerged as biomarkers for the progression to AD. However, the ultimate AD biomarker panel will likely involve the inclusion of novel CSF and blood biomarkers more precisely associated with confirmed pathophysiologic mechanisms to improve its reliability for detecting preclinical AD. This review highlights advancements in biological fluid and imaging biomarkers that are moving the field towards achieving the goal of a preclinical detection of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies revealed that Aβ began to accumulate up to 15–20 years prior to clinical symptoms of Alzheimer’s disease42,43.”
From Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology (2023) · cites this paper as [43]
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, R. C., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,214
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Cited by
Sorted by citations
Items 201–223 of 223
Dorfsman, D. A., Cai, D., Hamilton‐Nelson, K. L., Adams, L. D., Mena, P. R., Rodriguez, V. C., Sánchez, J. J., Valladares, G. S., Lopez, M., Whitehead, P. L., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261415933
Subregional limbic radiomics on FDG-PET provides accurate early detection of Alzheimer’s disease
Rasi, R., Güveniş, A., & Initiative, F. T. A. D. N. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02168-8 · Cited by 1
Sharma, S., Sharma, U., Sethiya, N. K., & Singh, L. (2026) · Current Aging Science · doi:10.2174/0118746098373086251201095903
Alzheimer’s Disease Accelerates Cerebral Atrophy by Over a Decade Compared to Healthy Aging
Jalalian, S., & Weickenmeier, J. (2026) · Annals of Biomedical Engineering · doi:10.1007/s10439-026-04059-z
Tomadesso, C. (2018) · theses.fr (ABES) · doi:10.70675/7fad6418zff81z49c7z984dz63aa2e44d7fc
Abdelouahab, O. B. (2021) · theses.fr (ABES) · doi:10.70675/97f4885fz3f5cz4234zb8e2ze3fa7c4e3d41
Exploration de nouveaux biomarqueurs plasmatiques pour le diagnostic de la maladie d’Alzheimer
Rossi, E. (2021) · theses.fr (ABES) · doi:10.70675/71230be4z1955z4fafzb1b8z8ff71a4edaff
Kamble, V., Kolekar, K. A., Dabhole, S., Bashir, B., Kumbhar, P., Disouza, J., & Patravale, P. V. B. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108479
Metabolic dysregulation in Alzheimer’s disease: Mechanisms, markers, and therapeutic prospects
Mittal, R., Priya, Banerjee, J., & Dixit, A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.011
Muralidhara, M., Vismaya, & Kumar, V. L. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106204
Synaptic dysfunction as a major driver in Alzheimer's disease: Beyond the amyloid paradigm
Mierzwa, N., & Wężyk, M. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106858
Ahmed, H. M., Al‐Hussainy, A. F., Arora, V., Rekha, M. M., Kundlas, M., Chennakesavulu, K., Manu, M., Rizaev, J., Taher, S. G., Alwan, M., et al. (2026) · Brain Imaging and Behavior · doi:10.1007/s11682-026-01181-3
Falahati, M., Ramezannejad, E., Vaez-Gharamaleki, Y., Radnia, P., Shahba, S., Rasoulian, P., Sara, R., Dasmeh, N., & Bemanalizadeh, M. (2026) · Research Square · doi:10.21203/rs.3.rs-10065374/v1
Vinothini Priya., G., & Arumugam, S. (2026) · International Conference on Sustainable Computing and Smart Systems (ICSCSS) · doi:10.1109/icscss69635.2026.11646122
Effect of dietary patterns on biomarkers in Alzheimer’s disease
Rezaeimanesh, N., Khodadadi, S., Montazeri‐Shatouri, R., Motahar, A. A., Hosseini, E., Owji, M., Negah, S. S., & Moghadasi, A. N. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.012
Electrodermal Activity as a Potential Diagnostic Biomarker for Alzheimer’s Disease: A Pilot Study
Pandian, S. S. R., Díaz, L. R. M., Ruiz-Triviño, J., Aguillon, D. F., & Posada-Quintero, H. F. (2026) · Sensors · doi:10.3390/s26175407
Azeez, S., Chinnadurai, R. K., Ponne, S., & Duraikkannu, D. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.07.004
Xiao, Z. (2026) · International Conference on Biomedicine and Bioinformatics Engineering (ICBBE) · doi:10.1145/3822183.3822283
Fatima, K., Cho, H., Olawuyi, I. F., & Lee, W. (2026) · Nutrition Research · doi:10.1016/j.nutres.2026.09.007
Rao, Y., Liu, L., Ostaszewski, B. L., Anderson, A. K., Pinilla, V., Shirzadi, Z., Laho, E. M., Stern, A. M., Yau, W. W., Yang, H., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218564
Xiao, H., Zhou, F., Xie, K., & Wang, T. (2026) · Human Brain · doi:10.15302/hb.2026.0004
Metadata
- Authors
- Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J.
- Affiliations
- Trinity Health Grand Rapids (US)
- Michigan State University (US)
- Barrow Neurological Institute (US)
- Corresponding author
- Mufson, Elliott J.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 14
- Issue
- 1
- Pages
- 35-53
- ISSN
- 1878-7479 (ISSN-L)
- PMC
- PMC5233625
- OpenAlex
- W2529983878
- Cited by
- 224
- References
- 296
- Citations by year
- 2026: 23 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 24 · 2021: 33 · 2020: 22 · 2019: 18 · 2018: 11 · 2017: 3
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Neurotherapeutics (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG043375, AG026032)
- National Intitute on Aging (AG042146)
- BNI Barrow and Beyond
- Saint Mary’s Foundation
- Miles for Memories of Battle Creek
- National Insitute of Aging (PO1AG025204)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, biomarkers, early detection, preclinical Alzheimer's disease, disease progression, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, phosphorylated tau, amyloid PET, tau PET, FDG-PET, blood biomarkers
- MeSH terms
- Alzheimer Disease, Autoantibodies, Humans, Sensitivity and Specificity, Biomarkers, Amyloid beta-Peptides, Disease Progression, Inflammation Mediators, Early Diagnosis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
